Dalfampridine Suppliers & Bulk Manufacturers
Available Forms: Extended-Release tablets (XR)
Available Strengths: 10 mg
Reference Brands: Ampyra(US)
Category:
Multiple sclerosis
Dalfampridine ER is a potassium channel blocker that enhances nerve signal conduction in damaged nerves. It improves walking speed and mobility in multiple sclerosis patients. Benefits include better gait, increased independence, and improved quality of life, supporting functional mobility and daily activity performance.
Product Description:
Dalfampridine extended-release (ER) tablets, marketed as Ampyra, are approved in the US by the FDA and in the EU via EMA for improving walking in multiple sclerosis (MS) patients. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial results and manufacturing standards, while the EMA ensures compliance with regional safety and quality standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing